Dianthus Therapeutics, Inc. /DE/ SEC filings DNTH

Dianthus Therapeutics, Inc. /DE/ has 658 filings in SEC EDGAR's recent list, going back to Nov 23, 2016. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Dianthus Therapeutics, Inc. /DE/ SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 9, 2026 —
DEF 14A Proxy statement Apr 9, 2026 May 21, 2026
DEFA14A Additional proxy material Apr 10, 2025 —
DEF 14A Proxy statement Apr 10, 2025 May 22, 2025
DEFA14A Additional proxy material Apr 11, 2024 —
DEF 14A Proxy statement Apr 11, 2024 May 23, 2024
DEFA14A Additional proxy material May 2, 2022 —
DEF 14A Proxy statement May 2, 2022 Jun 28, 2022
DEFA14A Additional proxy material Apr 21, 2021 —
DEF 14A Proxy statement Apr 21, 2021 Jun 1, 2021
DEFA14A Additional proxy material Apr 24, 2020 —
DEF 14A Proxy statement Apr 24, 2020 Jun 5, 2020
DEFA14A Additional proxy material Apr 25, 2019 —
DEF 14A Proxy statement Apr 25, 2019 Jun 7, 2019

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DNTH (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1690585
Former names
Magenta Therapeutics, Inc. (until Sep 8, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.